Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: A resonator includes an interdigital transducer provided with a main electrode area formed to a shape of a comb on a piezoelectric substrate by a reference pitch in such a manner as to have a unit length along a longitudinal direction thereof and one pair of first electrode areas constituted of one side first electrode area formed to a shape of a comb on the piezoelectric substrate by a first increment pitch obtained by increasing the reference pitch by a first value in such a manner as to have the unit length along the longitudinal direction and the other side first electrode area formed to a shape of a comb on the piezoelectric substrate by a first decrement pitch obtained by decreasing the reference pitch by almost the same value as the first value.

Abstract: An ion exchange resin and a method for preparing the same are provided. An ion exchange resin is formed by a composition, and the composition includes a crosslinking agent and an ionic compound with sulfonate ions. The ionic compound with sulfonate ions is formed by reacting an epoxy resin with an ionic monomer with sulfonate ions or an ionic polymer having sulfonate ions. The ionic monomer and the ionic polymer each has a hydroxyl group or an acid group at the ends. The ionic monomer or the ionic polymer is 40 to 80 parts by weight, and the epoxy resin is 15 to 25 parts by weight, based on 100 parts by weight of the ion exchange resin. An ion exchange resin with a network structure is formed after the ionic compound with sulfonate ions reacts with the crosslinking agent.

Abstract: Compounds are provided as chemokine inhibitors having the structure:

Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

Abstract: Systems, methods, and devices are described herein for integrated circuit (IC) layout validation. A plurality of IC patterns are collected which include a first set of patterns capable of being manufactured and a second set of patterns incapable of being manufactured. A machine learning model is trained using the plurality of IC patterns. The machine learning model generates a prediction model for validating IC layouts. The prediction model receives data including a set of test patterns comprising scanning electron microscope (SEM) images of IC patterns. Design violations associated with an IC layout are determined based on the SEM images and the plurality of IC patterns. A summary of the design violations is provided for further characterization of the IC layout.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: A display device includes a first substrate, a second substrate, a first conductive layer, a first insulating layer, a second conductive layer and a spacer. The second substrate is disposed opposite to the first substrate. The first conductive layer is disposed on the first substrate and includes the first conductive line and the first dummy pad thereon. The first dummy pad and the first conductive line are disposed adjacent to each other. The first insulating layer is disposed on the first conductive layer. The second conductive layer is disposed on the first insulating layer and include a conductive pad partially overlap the first dummy pad. The spacer is disposed between the first substrate and the second substrate and partially overlaps the first conductive line.

Abstract: The present invention relates to a transition metal compound for an olefin polymerization catalyst, represented by chemical formula 1. The description of chemical formula 1 is as described in the specification.

Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, Y, Y?, and the subscripts m and n are as defined herein.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R5, R6, R7, R8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: A method for mitigating extreme ultraviolet (EUV) mask defects is disclosed. The method includes the steps of providing a wafer blank, identifying a first plurality of defects on the wafer blank, providing an EUV mask design on top of the wafer blank, identifying non-critical blocks with corresponding stretchable zones on the EUV mask design, overlapping the EUV blank with the EUV mask design, identifying a second plurality of defects, the second plurality of defects are solved, identifying a third plurality of defects, the third plurality of defects are not solved, adjusting the relative locations of the EUV mask design and the EUV blank to solve at least one of the third plurality of defects, and adjusting the locations of at least one of the non-critical blocks within corresponding stretchable zones to solve at least one of the third plurality of defects.

Abstract: The present invention relates to a press-type water sampling device, and to a press-type water sampling device comprising: a water sampling bottle having opened upper and lower parts; and a bumper support, which has a top cap and a bottom cap for blocking the opened upper and lower parts of the water sampling bottle, is formed into a frame having a shape that encompasses the water sampling bottle, and enables the water sampling bottle to be vertically moveable.

Abstract: A method including decomposing a conflict graph based on a number of masked to be used to manufacture a semiconductor device. The method further includes determining whether the decomposed conflict graph is a simplified graph based on a comparison between the decomposed conflict graph and a stored conflict graph. The method further includes determining whether the decomposed conflict graph is colorable based on a number of masks used to pattern the layer of the semiconductor device. The method further includes indicating that the conflict graph is colorable in response to a determination that the decomposed conflict graph is colorable.

Abstract: A display device is disclosed, which includes a display area including a central region and a peripheral region. The display device includes: a first conductive line, a second conductive line, a first shielding portion and a second shielding portion. The first conductive line is disposed in the central region and extends along a first direction. The second conductive line is disposed in the peripheral region and extends along the first direction. The first shielding portion overlaps the first conductive line and comprises a first edge extending along the first direction and adjacent to the second conductive line. The second shielding portion overlaps the second conductive line and comprises a second edge extending along the first direction and away from the central region. A distance between the first conductive line and the first edge is different from a distance between the second conductive line and the second edge.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Boundary cells may be provided. A boundary of a first functional cell of a circuit is determined. A first plurality of a first type of dummy cells are placed along a first portion of the determined boundary. The first portion extends in a first direction. Each of the first type of dummy cells comprises first pre-defined dimensions. A second plurality of a second type of dummy cells are placed along a second portion of the determined boundary. The second portion extends in a second direction. Each of the second type of dummy cells comprises second pre-defined dimensions. The second pre-defined dimensions is different than the first pre-defined dimensions.

Abstract: The present invention discloses ventilation apparatus, comprising a casing with a first vent and a second vent, a fixed spacer disposed within the casing, and a movable spacer in operative connection with a power mechanism. Also discloses herein are methods for ventilating a subject, by synchronously providing a positive pressure ventilation and a negative pressure ventilation using the ventilation apparatus described herein.